[HTML][HTML] Anlotinib plus Icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).
D Huang, D Zhong, C Zhang, Y Zhang, Y Shang… - 2020 - ascopubs.org
9573 Background: Anti-angiogenic monoclonal antibodies plus EGFR TKIs have previously
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …
Sintilimab plus anlotinib as second‐or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A …
K Chen, Y Xu, Z Huang, X Yu, W Hong, H Li… - Cancer …, 2023 - Wiley Online Library
Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR
alterations typically have worse treatment outcomes than patients with classically EGFR …
alterations typically have worse treatment outcomes than patients with classically EGFR …
Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations …
Z Jiang, J Zhang, H Sun, C Wang, Y Zhang… - Thoracic …, 2021 - Wiley Online Library
Background This study focused on comparing the safety and therapeutic effects between
icotinib monotherapy and icotinib plus bevacizumab combined therapy in non‐small cell …
icotinib monotherapy and icotinib plus bevacizumab combined therapy in non‐small cell …
The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective …
L Wang, Y Li, L Li, Z Wu, D Yang, H Ma… - OncoTargets and …, 2018 - Taylor & Francis
Purpose This study was conducted to compare the efficacy of a combination of icotinib and
chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer …
chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer …
[HTML][HTML] The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized …
Y Zhao, Q Wang, L Zhang, J Shi, Z Wang… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background Anlotinib demonstrated improved overall survival (OS) and progression-free
survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with …
survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with …
Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: a multi‐center …
L Lei, W Wang, Y Zhu, J Li, Y Fang, H Wang… - Cancer …, 2020 - Wiley Online Library
The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR
uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential …
uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential …
[HTML][HTML] Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in …
T Li, Y Qian, C Zhang, J Uchino… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background The effect of anlotinib combined with epidermal growth factor receptor TKIs
(EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired …
(EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired …
[HTML][HTML] Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: a single-group, open …
H Hayashi, K Yonesaka, A Nakamura, D Fujimoto… - Lung Cancer, 2022 - Elsevier
Introduction Alternation of osimertinib and afatinib is a potential approach to overcome
osimertinib resistance and to allow complementation of drug efficacy without compromising …
osimertinib resistance and to allow complementation of drug efficacy without compromising …
[HTML][HTML] Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
SJ Sun, JD Han, W Liu, ZY Wu, X Zhao… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Icotinib could have potential effect and tolerability when used sequentially
with chemotherapy for advanced epidermal growth factor receptor (EGFR)-mutated non …
with chemotherapy for advanced epidermal growth factor receptor (EGFR)-mutated non …